Ivan Nemazanyy1,2,3, Guillaume Montagnac4, Ryan C Russell5,6, Lucille Morzyglod3,7,8, Anne-Françoise Burnol3,7,8, Kun-Liang Guan5,6, Mario Pende1,2,3, Ganna Panasyuk1,2,3. 1. Institut Necker-Enfants Malades (INEM), Cedex 14, 75993 Paris, France. 2. Institut National de la Santé et de la Recherche Médicale (INSERM), Cedex 14, U1151, 75993 Paris, France. 3. Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France. 4. Institut National de la Santé et de la Recherche Médicale (INSERM), U1170, Gustave Roussy Institute, 94805 Villejuif, France. 5. Department of Pharmacology, University of California at San Diego, La Jolla, California 92093, USA. 6. Moores Cancer Center, University of California at San Diego, La Jolla, California 92093, USA. 7. Institut National de la Santé et de la Recherche Médicale (INSERM), U1016, Institut Cochin, 75014 Paris, France. 8. Centre national de la recherche scientifique (CNRS), UMR8104, 75014 Paris, France.
Abstract
Defective hepatic insulin receptor (IR) signalling is a pathogenic manifestation of metabolic disorders including obesity and diabetes. The endo/lysosomal trafficking system may coordinate insulin action and nutrient homeostasis by endocytosis of IR and the autophagic control of intracellular nutrient levels. Here we show that class III PI3K--a master regulator of endocytosis, endosomal sorting and autophagy--provides negative feedback on hepatic insulin signalling. The ultraviolet radiation resistance-associated gene protein (UVRAG)-associated class III PI3K complex interacts with IR and is stimulated by insulin treatment. Acute and chronic depletion of hepatic Vps15, the regulatory subunit of class III PI3K, increases insulin sensitivity and Akt signalling, an effect that requires functional IR. This is reflected by FoxO1-dependent transcriptional defects and blunted gluconeogenesis in Vps15 mutant cells. On depletion of Vps15, the metabolic syndrome in genetic and diet-induced models of insulin resistance and diabetes is alleviated. Thus, feedback regulation of IR trafficking and function by class III PI3K may be a therapeutic target in metabolic conditions of insulin resistance.
Defective hepatic insulin receptor (IR) signalling is a pathogenic manifestation of metabolic disorders including obesity and diabetes. The endo/lysosomal trafficking system may coordinate insulin action and nutrient homeostasis by endocytosis of IR and the autophagic control of intracellular nutrient levels. Here we show that class III PI3K--a master regulator of endocytosis, endosomal sorting and autophagy--provides negative feedback on hepatic insulin signalling. The ultraviolet radiation resistance-associated gene protein (UVRAG)-associated class III PI3K complex interacts with IR and is stimulated by insulin treatment. Acute and chronic depletion of hepatic Vps15, the regulatory subunit of class III PI3K, increases insulin sensitivity and Akt signalling, an effect that requires functional IR. This is reflected by FoxO1-dependent transcriptional defects and blunted gluconeogenesis in Vps15 mutant cells. On depletion of Vps15, the metabolic syndrome in genetic and diet-induced models of insulin resistance and diabetes is alleviated. Thus, feedback regulation of IR trafficking and function by class III PI3K may be a therapeutic target in metabolic conditions of insulin resistance.
Catabolic and anabolic processes are tightly coordinated in response to nutrient and energy availability. The trafficking of endocytic and autophagic vacuoles to the lysosomal degradation system is a key event to satisfy the energetic needs of the cell after food intake or during starvation. Insulin, the major anabolic hormone in mammals, is released by pancreatic beta cells into the bloodstream after food intake and acts in peripheral tissues by binding transmembrane insulin receptor (IR) with tyrosine kinase activity1. The endocytosis of IR plays an important role in the magnitude and nature of insulin signals. Depending on the tissues, IR can be internalized at the caveolae, which are invaginations of the plasma membrane, or at clathrin-coated pits234. The internalization of IR and sorting to the lysosomes is a major pathway to degrade receptor and to remove hormone from the circulation thus terminating insulin action15. However, in the endosomes, IR maintains its activity and interacts with signal transduction elements6. Insulin receptor substrates (IRS1–4) act as signalling scaffolds at both the plasma membrane and endosomes, where essential proteins for the metabolic action of insulin are recruited, such as class I PI3K, IRS and Akt kinases178. In addition to being regulated by the endo/lysosomal system, insulin signalling tightly controls autophagy. Autophagy is a process by which proteins and organelles are engulfed in double-membrane autophagosomes and degraded after fusion with lysosomes9. Insulin inhibits the autophagic degradation of cellular components, while favouring nutrient uptake and usage from the extracellular milieu. Consistent with a central role in nutrient homeostasis, a growing body of evidence indicates that defects in the endocytosis and autophagy may contribute to metabolic syndromes10. Defects in IR internalization have been associated with obesity and type 2 diabetes (T2D), both in humans and in animal models1112. Autophagy defects have a complex and controversial influence on insulin resistance and nutrient homeostasis131415.Among the molecular mechanisms coordinating endocytosis and autophagy, class III PI3K has a central evolutionarily conserved role. Class III PI3K is present in every eukaryotic cell, from yeast, in which it was initially discovered, to mammals16. It is constituted by a complex of the regulatory and catalytic subunits Vps15 and Vps34, respectively. Vps15 is a putative serine/threonine protein kinase, which is required for Vps34 stability, activity and membrane targeting17. The lipid kinase activity of Vps34 is a major source of phosphatidylinositol 3-phosphate (PI3P) in the cell, which functions as secondary messenger at the intracellular membranes and docking signal for proteins containing PI3P-binding domains, such as FYVE or PX (ref. 18). Binding to PI3P promotes the formation of protein scaffolds that are involved in multiple processes, including autophagy, trafficking from the plasma membrane towards the lysosome and endosomal sorting. Both autophagic and endocytic trafficking require class III PI3K activity. It is now becoming clear that class III PI3K contributes to these pleiotropic functions by engaging in distinct protein complexes. Binding of Atg14-related protein (ATG14) or ultraviolet radiation resistance-associated gene protein (UVRAG) to a Vps34/Vps15/Beclin-1 complex is mutually exclusive1920. The ATG14-containing complex stimulates Vps34 activity at the phagophore membranes and is required for autophagy initiation in response to nutrient withdrawal. The UVRAG-containing complex is implicated in endosome and autophagosome maturation. The majority of Vps34/Vps15 in mammalian cells is not in complex with ATG14 and UVRAG, the existence of additional complexes is likely21.Vps34/Vps15 activity is now thought to integrate environmental cues. Glucose starvation increases class III PI3K activity, in both ATG14- and UVRAG-containing complexes, through an AMP-activated kinase (AMPK)-dependent mechanism22. During conditions of amino-acid starvation that promote autophagy, class III PI3K activity in ATG14-containing complexes is specifically stimulated, whereas the majority of Vps34 complexes are inhibited. This is due to the ability of ATG14 to recruit the Ulk1 kinase, which is activated by amino-acid starvation and phosphorylates Beclin-1 to promote autophagy23. Less clear is the impact of insulin on class III PI3K activity. Although insulin does not appear to affect total class III PI3K activity24, the effect of insulin treatment on specific Vps34/Vps15 complexes has never been reported.We show that UVRAG-containing class III PI3K complexes are effectors of insulin action that associate with IR. Moreover, perturbing class III PI3K activity has a major impact on the kinetics of IR degradation, as well as on downstream signal transduction. As a result, we demonstrate that targeting Vps15 has a beneficial metabolic effect in mouse models of obesity and T2D. These data define class III PI3K as a crucial element in the response to insulin and nutrients (glucose and amino acids) at the crossroad of autophagy and IR trafficking.
Results
Loss of Vps15 delays IR degradation and promotes signalling
To analyse the role of class III PI3K in IR responses and metabolic homeostasis, we first depleted Vps15 using a specific shRNA in mouse hepatocellular carcinoma Hepa1.6 cells. In line with its requirement for the class III PI3K complex stability25, the downregulation of Vps15 was paralleled by decreased levels of other core components of the complex—Vps34 and Beclin-1 (Fig. 1a). We revealed that Akt signalling, a major downstream effector of activated IR8, was upregulated in Vps15-depleted cells (Fig. 1a and Supplementary Fig. 1a), as indicated by increased phosphorylation of Akt and its substrate proline-rich Akt substrate of 40 kDa (Pras40) protein. These observations prompted us to hypothesize that IR turnover could be affected in Vps15-depleted cells. To test this possibility, we followed IR levels on insulin stimulation. In control scrambled hairpin (shSCR)-treated cells, 50% of the catalytic subunit of IR, IRβ, was degraded 3 h after insulin stimulation (Fig. 1b and Supplementary Fig. 1a), suggesting receptor internalization and degradation in the lysosomes on exposure to the agonist. Interestingly, depletion of Vps15 impaired IRβ degradation, concomitant with increased insulin signalling, as measured by Akt phosphorylation (Fig. 1b and Supplementary Fig. 1a). Importantly, the effects of Vps15 depletion on IR levels and downstream Akt activation could be rescued by overexpression of recombinant hVps15 protein resistant to shRNA (Fig. 1c). In addition, the improved insulin signalling in Vps15-depleted cells was evidenced by increased complexes between IR and its downstream effectors (Supplementary Fig. 1b,c). Next, we analysed primary hepatocytes from Vps15f/f mice transduced with Cre recombinase-expressing adenoviral vector. As previously observed26, CRE-mediated recombination of exon 2 in Vps15 gene led to the expression of non-functional truncated Vps15 protein due to the usage of alternative start codon in the exon 4 (Supplementary Fig. 2a). As expected, depletion of Vps15 in hepatocytes resulted in loss of class III PI3K complex expression (Supplementary Fig. 2a). Importantly, IR levels decreased in control hepatocytes on insulin stimulation, while they remained constant in mutant cells (Supplementary Fig. 2b,c). Importantly, the insulin-stimulated IR degradation to large extend could be rescued by inhibition of lysosomal activity confirming that the lysosomal pathway is a major route of receptor degradation (Supplementary Fig. 2b). The lower basal levels of IRβ in primary cultures of Vps15-depleted hepatocytes likely reflected compensatory mechanisms due to persistent pathway activation. Consistent with the results in Hepa1.6 cells, insulin-stimulated Akt phosphorylation was also upregulated in Vps15-depleted hepatocytes (Supplementary Fig. 2c). In sum, both in hepatocellular carcinoma cells and in primary hepatocytes Vps15 depletion interferes with IR degradation and results in improved Akt signalling.
Figure 1
IR signalling is induced in Vps15-depleted cells.
(a) Hepa1.6 cells were transduced with adenoviral vectors expressing shRNA Vps15 or shRNA SCR as a negative control. The 48-h post-transduction expression of components of class III PI3K and status of Akt-signalling pathway was revealed by immunoblot analysis. Immunoblot with anti-GAPDH antibodies was used as a loading control. Densitometric analyses of phosphorylated proteins normalized to total protein levels are presented on Supplementary Fig. 1a. (b) Hepa1.6 cells were transduced with shRNA Vps15- or shRNA SCR-expressing adenoviruses. The 24-h postinfection cells were serum starved for 24 h followed by stimulation with 1 μM insulin (Ins). IR levels and status of the pathway activation was determined by immunoblot analysis. Densitometric analyses of phosphorylated Akt normalized to total Akt level and actin-normalized IRβ levels are presented on Supplementary Fig. 1a. (c) Hepa1.6 cells were transduced with GFP, shRNA Vps15 or shRNA Vps15 in combination with hVps15 cDNA-expressing adenoviruses. The 24-h postinfection cells were serum starved for 24 h followed by stimulation with 1 μM insulin for 1 h. IR levels and status of Akt-signalling pathway activation was determined by immunoblot analysis. (d) Vps15f/f primary hepatocytes were transduced with Adeno-β-Gal- or Adeno-CRE-expressing vectors. To detect endogenous PI3P, 48-h postinfection hepatocytes were transfected with the reporter plasmid expressing 2xFYVE-GFP fusion protein. Cells were kept in the nutrient-rich media supplemented with 10% FBS and insulin, 24-h post-transfection cells were PFA fixed and PI3P-positive compartments (endosomes) were visualized by confocal microscopy. Scale bar, 10 μm. (e) Vps15f/f primary hepatocytes were transduced with Adeno-GFP or Adeno-CRE vectors. Cells were kept in the nutrient-rich media supplemented with 10% FBS and insulin. The 72-h post-transduction cells were collected and endosomal fraction prepared from the equal mass of cells. Equal volumes of endosomal fraction were loaded for Adeno-GFP or Adeno-CRE samples. Total protein extracts were prepared from the fraction of pelleted cells. The protein concentration in the extracts was measured by Bradford and the equal amount of proteins (10 μg) was loaded for each sample. Proteins present in endosomal fraction and in total extracts were revealed by immunoblot analysis. Immunoblot with anti-VDAC, anti-GAPDH and anti-Tubulin antibodies served as a control of purity of endosomal fraction for mitochondria proteins, cytoplasmic proteins and cytoskeletal proteins, respectively.
Vps15 inactivation results in accumulation of the endosomes
Class III PI3K-dependent production of PI3P on endosomes is required for the recruitment of PI3P-binding domain-containing proteins that regulate different steps of endocytosis. In agreement, Vps15 depletion impaired the recruitment of the PI3P probe 2xFYVE to the endosomal compartment, providing additional evidence for the loss of class III PI3K activity in Vps15-depleted cells (Fig. 1d). Perturbed endosomal plasticity on Vps15 loss in primary hepatocytes was further evidenced by striking vacuolization and expansion of the Lamp1-positive compartment (Supplementary Fig. 2d). Similarly, the immunofluorescent studies of Hepa1.6 cells revealed profound perturbations of endolysosomal compartment on short-term Vps15 downregulation (Supplementary Fig. 1d). In addition, endosome purification by differential centrifugation in sucrose gradient revealed increased levels of endosomal markers in Vps15 mutant hepatocytes, as assessed by the immunoblot analysis of the early and late endosomal proteins Rab5 and Lamp1, respectively (Fig. 1e). Of note, in Vps15-depleted cells compared with green fluorescent protein (GFP)-transduced cells, IRβ levels were enriched in the endosomal fraction unlike in total cell extracts.
Slow kinetics of IR trafficking in Vps15-depleted cells
To study the dynamics of IR trafficking we transiently overexpressed red fluorescent protein (RFP)-tagged human IRβ. RFP-IRβ was detected at the plasma membrane and in small endosomes in control and Vps15-depleted Hepa1.6 cells (Fig. 2a). RFP-IRβ was also present on enlarged vacuolar endosomes uniquely in Vps15-depleted cells, suggesting strong endocytic trafficking defects of the receptor (Fig. 2a). We performed live cell imaging of these cells to track RFP-IRβ-labelled endosomes and quantified their movement parameters (Supplementary Movie). The tracking of RFP-IRβ-positive small endosomes revealed that Vps15 inactivation resulted in a global reduction of the velocity of this population (Fig. 2b). This was further reflected by a 50% decrease in the average velocity of RFP-IRβ-positive endosomes (Fig. 2c). Together, these data reveal the accumulation of IR on enlarged and static endosomes on Vps15 depletion. These observations also suggest that defective IR degradation observed in Vps15-inactivated cells is a direct consequence of trafficking defect that delays receptor delivery into lysosomes.
Figure 2
IR trafficking is impaired on class III PI3K inactivation.
(a) Hepa1.6 cells were transduced with shRNA Vps15- or shRNA SCR-expressing adenoviruses. IRβ-RFP was overexpressed 24 h postinfection and cells were imaged 24 h post-transfection. Representative spinning disc confocal snap shot image of the live cell used for endosome tracking is presented (the corresponding movie is available as a Supplementary Information File). Endosomes were manually tracked using MetaMorph software. Cumulative endosome velocity (b) and average endosome velocity (c) were calculated for each endosome. Data are means±s.d. (n=95–125 endosomes, *P<0.001 versus Adeno-shRNA SCR, Mann–Whitney Rank-sum test). (d) Hepa1.6 cells were transduced with shRNA Vps15- or GFP-expressing adenoviruses. The 24-h postinfection cells were serum starved for 24 h followed by stimulation with 1 μM insulin for 2 h. Before stimulation with insulin, cells were pretreated with 3 μM of PitStop2 inhibitor for 15 min. IRβ levels and status of the pathway activation was determined by immunoblot analysis. Densitometric analyses of phosphorylated Akt and Pras40 normalized to levels of total proteins are presented on Supplementary Fig. 1e.
Block of endocytosis improves IR signalling
To confirm that defects in receptor degradation lead to improved IR signalling in Vps15-depleted cells, IR internalization and trafficking was blocked using the selective inhibitor of clathrin function, PitStop2 (ref. 27). As expected, endocytosis inhibition in control cells largely prevented IRβ degradation resulting in increased IRβ tyrosine phosphorylation (Fig. 2d). On the contrary, clathrin inhibition had no effect on IRβ stability and phosphorylation in Vps15-depleted cells. Importantly, the interference with IRβ endocytic trafficking and degradation in control cells mimicked the effect of Vps15 depletion on insulin signalling as evidenced by increased Akt phosphorylation and phosphorylation of its downstream target Pras40 (Fig. 2d and Supplementary Fig. 1e). Altogether, these results demonstrate that IR signalling is potentiated on class III PI3K inactivation in concomitance with altered kinetics of IR endocytic trafficking.
Insulin stimulates UVRAG-associated class III PI3K activity
Since IR signalling is negatively regulated by class III PI3K, we asked whether the activity of class III PI3K could be sensitive to insulin. While an increase in cellular PI3P levels has been reported, no significant changes in hVps34 activity on insulin stimulation have been observed242829. Recent reports demonstrated that measurement of total class III PI3K activity immunoprecipitated with anti-Vps34 antibody is not informative as Vps15/Vps34 proteins are engaged in complexes with different functions and regulation21. We measured class III PI3K activity associated with ATG14 and UVRAG, two mutually exclusive binding proteins of the core Vps34/Vps15 complex (Supplementary Fig. 3a). In agreement with recent reports22 and consistent with autophagy activation, Vps34 activity in ATG14 complex was significantly increased in response to amino-acid withdrawal (Fig. 3a). At the same time, UVRAG-associated Vps34 activity was insensitive to amino-acid deprivation (Fig. 3a). To determine whether class III PI3K activity is regulated by insulin, we analysed total Vps34 and UVRAG- or ATG14-associated Vps34 lipid kinase activity in primary hepatocytes, which were insulin starved and then stimulated for different times. Consistent with earlier reports, total Vps34 activity was not modified in response to insulin (Fig. 3b). Measurements of ATG14-associated Vps34 lipid kinase activity revealed that in contrast to amino-acid starvation, it was unchanged by insulin stimulation. However, insulin stimulation resulted in twofold increase of Vps34 activity in UVRAG-containing complexes (Fig. 3b). In addition, co-immunoprecipitation studies revealed that IR interacts with ectopically expressed Flag-tagged UVRAG complexes (Fig. 3c). Further studies revealed that in primary hepatocytes complex between endogenous IR and regulatory subunits of class III PI3K, Vps15 and UVRAG was induced by insulin stimulation (Fig. 3d and Supplementary Fig. 3c). Immunoprecipitation experiments followed by class III PI3K biochemical assay further confirmed that active Vps34 was in complex with endogenous IR (Supplementary Fig. 3d). Mechanistically, insulin stimulation of primary hepatocytes resulted in dissociation of Rubicon, a negative regulator of Vps34 activity in UVRAG-containing complexes (Fig. 3e). Altogether, these data demonstrate that distinct class III PI3K complexes are differently regulated in response to nutrient starvation and insulin stimulation revealing unappreciated crosstalk between IR signalling and class III PI3K activity regulation.
Figure 3
UVRAG-associated class III lipid kinase is activated by insulin.
(a) ATG14- and UVRAG-containing Vps34 complexes were immunoprecipitated from Hepa1.6 cells grown in the presence (NR) or absence of amino acids (−AA) and assayed for lipid kinase activity. Inputs for each assay were immunoblotted to determine the amounts of the Vps34 co-immunoprecipitated. PI3P signals were densitometrically measured and normalized to Vps34 protein levels. The data are presented as a fold difference of PI3P normalized to co-immunoprecipitated Vps34 levels revealed by immunoblot for each condition. Data are means±s.e.m. (n=4, *P<0.05 versus NR, two-tailed, unpaired Student's t-test). (b) ATG14- and UVRAG-containing Vps34 complexes were immunoprecipitated from primary hepatocytes, which were serum starved for 24 h followed by stimulation with 1 μM insulin (Ins) and assayed for lipid kinase activity. PI3P signals were densitometrically measured. The data are presented as a fold difference of PI3P normalized to co-immunoprecipitated Vps34 levels revealed by immunoblot for each condition. Data are means±s.e.m. (n=3, *P<0.05 versus starved cells, two-tailed, unpaired Student's t-test). Representative immunoblot analyses of ATG14, UVRAG and Vps34 co-immunoprecipitates are presented as Supplementary Fig. 3a and Supplementary Fig. 3b. (c) Primary hepatocytes were transiently transfected with UVRAG–Flag cDNA-expressing vector 12 h post-plating and were kept in the serum containing media. The 36-h post-transfection cells were collected and UVRAG–Flag complexes were immunoprecipitated with anti-Flag antibody. The presence of IRβ and class III PI3K subunits in the immunoprecipitation eluates was revealed by immunoblot. (d) Endogenous IRβ was immunoprecipitated from primary hepatocytes, which were serum starved for 24 h and stimulated with 1 μM insulin. The presence of Vps15 and IRβ in the immunoprecipitation eluates was revealed by immunoblot. Densitometric analyses of co-immunoprecipitated endogenous Vps15 normalized to IRβ are presented as fold difference over the unstimulated condition. Data are means±s.e.m. (n=3, *P<0.05 versus starved cells, two-tailed, unpaired Student's t-test). (e) UVRAG-containing complexes were immunoprecipitated from primary hepatocytes, which were serum starved for 24 h followed by stimulation with 1 μM insulin for indicated times. Immunoprecipitated endogenous class III PI3K subunits were revealed by immunoblotting. Densitometric analyses of co-immunoprecipitated endogenous Rubicon normalized to UVRAG are presented as fold difference over the unstimulated condition. Data are means±s.e.m. (n=3, *P<0.05 versus starved cells, two-tailed, unpaired Student's t-test). The protein G beads served as a control of the nonspecific binding in c–e.
Next, we sought to determine the consequences of class III PI3K inactivation on IR signalling and metabolic homeostasis in vivo. We recently demonstrated that Vps15 is an essential gene product, as witnessed by the early embryonic lethality of whole body Vps15 knockout mutants26. To circumvent the embryonic lethality and to address the role of Vps15 in tissue insulin response, hepatic Vps15 was targeted in vivo in adult mice by CRE recombinase delivered through intravenous injection of adenoviral vectors. The selectiveness of this approach to hepatic tissue was evidenced by lack of Vps15 gene recombination and unaffected Vps15 protein expression in other tissues (Supplementary Fig. 4a,b). Effective depletion of hepatic Vps15 expression was confirmed both at transcript and protein levels revealing an 80% decrease of Vps15 levels in CRE-expressing livers (Supplementary Fig. 4c–e). Analysis of Vps15f/f mice 10 days postinjection revealed that adenoviral CRE-treated mice developed liver hypertrophy (Fig. 4a and Supplementary Fig. 4f). Liver hypertrophy of Vps15-depleted mice was due to increase in hepatocyte cell size and cell number (Fig. 4b and Supplementary Fig. 4g). In addition, hepatocytes in adenoviral CRE-transduced livers developed striking vacuolization (Fig. 4b). In agreement with the requirement of class III PI3K for autophagy, the acute deletion of Vps15 resulted in autophagy block, as revealed by the accumulation of an autophagy cargo receptor, p62/SQSTM1, increased levels of the unconjugated form of LC3 (LC3-I) and a reduction of lipidated LC3 (LC3-II) (Supplementary Fig. 4c). Consistent with the data in cultured cells, hepatic Akt signalling was activated in Vps15 mutant mice under refeeding conditions (Supplementary Fig. 5a). Importantly, acute short-term hepatic depletion of Vps15 affected whole-body glucose metabolism, as adenoviral CRE-injected mice showed significant hypoglycaemia in starvation conditions and in response to an intraperitoneal glucose challenge (Fig. 4c). In sum, similarly to in vitro models, short-term depletion of Vps15
in vivo potentiates insulin signalling and impacts whole-body glucose metabolism.
Figure 4
Increased insulin action in Vps15 hepatic mutants.
(a) Liver weight to body weight ratio of random-fed Vps15f/f mice 10 days post-transduction with Adeno-GFP or Adeno-CRE vectors. Data are means±s.e.m. (n=5–6, *P<0.05: versus Adeno-GFP, two-tailed, unpaired Student's t-test). (b) H&E-stained liver sections of random-fed Vps15f/f mice 10 days post-transduction with Adeno-GFP or Adeno-CRE vectors showing marked vacuolization of hepatocytes in livers of Adeno-CRE-transduced mice. Scale bar, 100 μm. (c) Intraperitoneal GTT in overnight fasted Vps15f/f mice 7 days post-transduction with Adeno-GFP or Adeno-CRE vectors. The histogram of the average value of the area under the respective curve calculated with GraphPadPrizm5 software is presented. Data are means±s.e.m. (n=5–6, *P<0.05 versus Adeno-GFP, two-tailed, unpaired Student's t-test). (d) Immunoblot analysis of total protein liver extracts of random-fed 2-month-old Vps15f/f and AlbCre+;Vps15f/f using indicated antibodies. Densitometric analyses of phosphoprotein levels normalized to total protein presented as folds over Vps15f/f. Data are means±s.e.m. (n=4–5, *P<0.05 versus Vps15f/f, two-tailed, unpaired Student's t-test). (e) Immunoblot analysis of total protein liver extracts of starved for 12 h or starved for 12 h followed by injection of insulin 2-month-old Vps15f/f and AlbCre+;Vps15f/f mice. Densitometric analyses of phosphoprotein levels normalized to total protein presented as folds over starved Vps15f/f. Data are means±s.e.m. (n=3, *P<0.05: versus Vps15f/f, two-tailed, unpaired Student's t-test). (f) Intraperitoneal insulin tolerance test performed on starved for 6 h 6-week-old Vps15f/f and AlbCre+;Vps15f/f mice. The histogram of an average value of the area under the respective curve was calculated with GraphPadPrizm5 software. Data are means±s.e.m. (n=8–14, *P<0.05 versus Vps15f/f, two-tailed, unpaired Student's t-test).
Akt signalling is augmented in hepatic mutants of Vps15
Next, we generated the liver-specific Vps15 knockout mice (herein referred as Vps15 LKO). To obtain Vps15 LKO mice, the Vps15f/f mice were crossed with transgenic line overexpressing CRE under the mouse albumin enhancer/promoter. Alb-Cre drives liver-specific CRE expression starting at E13.5 and achieves efficient deletion of targeted gene at early postnatal stage both in hepatocytes and biliary cells30. The loss of hepatic Vps15 expression was evidenced by transcript and protein analysis of the livers of Vps15 LKO mice (Supplementary Fig. 6a,b). Vps15 LKO mice recapitulated the main features observed after short-term Vps15 depletion by adenoviral CRE transduction: hepatomegaly due to increased cell size and cell proliferation (Supplementary Fig. 6c–e), vacuolization (Supplementary Fig. 6f) and autophagy block witnessed by accumulation of p62, LC3 (LC3-I/II) and polyubiquitinated proteins (Supplementary Fig. 6b). Consistent with the observations in Hepa1.6 cells (Fig. 2a–d and Supplementary Fig. 1d), the IR trafficking defects in mutant hepatocytes were highlighted by the perturbations of endolysosomal compartment and accumulation of endogenous IR in Vps15-null hepatocytes (Supplementary Fig. 6g). Altogether, Vps15 LKO recapitulates the autophagy and IR trafficking defects observed both in vitro and in vivo on Vps15 depletion.Importantly, increased hepatic insulin signalling was observed in Vps15 LKO mice both in random-fed and on insulin challenge conditions, as witnessed by Akt and FoxO1 phosphorylation (Fig. 4d,e). Similarly to cell cultures, increased IR tyrosine phosphorylation was detected in the liver extracts of Vps15 mutants compared with controls (Supplementary Fig. 7a). These data were consistent with the improved insulin and glucose tolerance after an intraperitoneal load observed in hepatic Vps15 LKO mice (Fig. 4f and Supplementary Fig. 7b). Interestingly, despite the autophagy block the hepatic Vps15 mutant did not present with steatosis as reported for other mouse models of deficient autophagy143132. On the contrary, the hepatic tissue of mice after chronic (Supplementary Fig. 8a,b) or acute (Supplementary Fig. 8e,f) Vps15 depletion was characterized by significantly lower hepatic lipid content. This was accompanied by decreased expression of lipogenic enzymes and marked increase in expression of lipases (Supplementary Fig. 8c). In addition, loss of hepatic Vps15 resulted in potent induction of glycolytic enzyme expression both on transcript and protein levels (Supplementary Fig. 9). The switch in expression of hepatic isoforms of hexokinase and pyruvate kinase to HK2 and PKM2 was observed in the livers of Vps15 mutants (Supplementary Fig. 9). Given increased hepatic insulin signalling and striking rearrangements in the expression of metabolic enzymes observed on hepatic Vps15 depletion, we compared the metabolic rates of age matched controls and Vps15 LKO mice. Vps15 LKO mice compared with littermate controls showed consistently higher oxygen consumption and energy expenditure in course of measurement (Supplementary Fig. 10a,b). This was accompanied by significantly augmented respiratory exchange ratio in Vps15 knockouts compared with controls suggesting the preferable utilization of carbohydrates as an energy source (Supplementary Fig. 10c). In addition, we did not observe significant difference in cumulative food or drink intake between experimental groups (Supplementary Fig. 10d). The increased metabolic activity of hepatic Vps15 mutants was most evident during the light phase of the cycle, which is in agreement with the increased activity of Vps15 mutant mice observed (Supplementary Fig. 10e).The ameliorated metabolic parameters of Vps15 LKOs were further observed under nutrient challenge, where Vps15 control and mutant mice were submitted to 2-week long high-fat diet (HFD) regimen. As expected, after 2 weeks of HFD, the control mice developed significant glucose intolerance (Supplementary Fig. 7b). Remarkably, hepatic Vps15 mutants, unlike controls, were protected from deleterious metabolic effect of HFD (Supplementary Fig. 7b). Improved insulin sensitivity on hepatic Vps15 loss was also accompanied by significantly lower circulating levels of insulin both on chow and HFD in random-fed Vps15 LKO mice (Supplementary Fig. 7c).Earlier studies addressed the causative link between the impaired autophagic flux and insulin resistance14. The study by Yang et al.14 demonstrated that the metabolic phenotype of ob/ob mice could be improved by increasing autophagic flux through ATG7 overexpression. In a somewhat contradictory fashion, recent work by Kim et al. suggested that the block of autophagy flux in Atg7 skeletal muscle or liver mutants led to endoplasmic reticulum (ER) stress and resulted in activation of ATF4 transcription factor responses, leading to the induction of Fgf21 and protection of mice from the detrimental effects of HFD feeding13. In Vps15 LKO mice, we did not observe induction of hepatic Fgf21 mRNA expression (Supplementary Fig. 7d). In addition, Fgf21 levels measured in plasma of control and Vps15 LKO mice did not reveal significant differences between two genotypes in random-fed or in starved conditions (Supplementary Fig. 7e).
Defective gluconeogenesis in Vps15 mutants
The suppression of gluconeogenesis is a major hypoglycaemic action of insulin in liver. To elucidate the mechanisms of improved glucose tolerance in Vps15 LKO, the expression of gluconeogenic enzymes was determined. Expression of key gluconeogenic enzymes was severely suppressed in both models of Vps15 deficiency, in Vps15 LKO mice (Fig. 5a,b) and after short-term depletion by adenoviral CRE transduction (Supplementary Fig. 11a,b). Furthermore, the expression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α), a transcriptional coactivator that is essential for the expression of genes of the gluconeogenesis pathway, was significantly downregulated in the livers of floxed mice injected with Adeno-CRE vectors (Supplementary Fig. 5b). In addition, hepatic expression of PGC1α as well as the gluconeogenic enzymes was inhibited even in starved mice and to great extent resistant to refeeding after Vps15 depletion (Supplementary Fig. 5b). Functionally, pyruvate tolerance test in Vps15 LKO mice revealed a profound defect in glucose production in response to a pyruvate challenge (Fig. 5c). Next, to confirm the effects of class III PI3K inactivation on glucose metabolism in a cell autonomous model, Vps15 was depleted in primary hepatocytes using adenoviral vectors expressing shRNA. As shown in Fig. 5d,e, Vps15 knockdown in primary wild-type hepatocytes significantly reduced expression of rate-limiting enzymes in the gluconeogenesis pathway, including G6PC and PEPCK. The later effect could be rescued by concomitant overexpression of shRNA-resistant hVps15 (Supplementary Fig. 11c). Notably, the acute depletion of Vps15 in primary hepatocytes was sufficient to inhibit gluconeogenesis, as evidenced by the drop in glucose release in response to pyruvate/lactate addition (Fig. 5f). Thus, interference with Vps15 expression in vitro and in vivo is associated with impaired gluconeogenesis.
Figure 5
Gluconeogenesis is impaired in hepatic Vps15 mutants.
(a) Relative mRNA expression levels of genes implicated in gluconeogenesis in the livers of 1-month-old random-fed Vps15f/f and AlbCre+;Vps15f/f mice. Data are means±s.e.m. (n=5–8, *P<0.05 versus Vps15f/f, two-tailed, unpaired Student's t-test). (b) Immunoblot analysis of total protein liver extracts of random-fed 1-month-old Vps15f/f and AlbCre+;Vps15f/f using G6PC antibody. Immunoblot with anti-tubulin antibody served as loading control. (c) Intraperitoneal pyruvate tolerance test performed on overnight-starved 6-week-old Vps15f/f and AlbCre+;Vps15f/f mice (n=5–8, *P<0.05 versus Vps15f/f, two-tailed, unpaired Student's t-test). The histogram of an average value of the area under the respective curve was calculated with GraphPadPrizm5 software (n=5–8, *P<0.05 versus Vps15f/f, two-tailed, unpaired Student's t-test). (d) Immunoblot analyses of cell extracts of primary hepatocytes transduced with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors with indicated antibodies. Primary hepatocytes were transduced and cells were collected 48 h postinfection for further analysis. Immunoblot with anti-tubulin antibody served as a loading control. (e) Relative mRNA expression levels of gluconeogenic enzymes in primary hepatocytes transduced with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. Cells were collected 48 h postinfection. Data are means±s.e.m. (n=3, *P<0.05 versus shRNA SCR infected, two-tailed, unpaired Student's t-test). (f) Glucose production by primary hepatocytes transduced with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. Primary hepatocytes 48 h postinfection were incubated for 12 h in glucose-free DMEM containing lactate/pyruvate (10:1 mM). Glucose content in the media was assayed enzymatically and normalized to protein content. Data are means±s.e.m. (n=6, *P<0.05 versus shRNA SCR infected, two-tailed, unpaired Student's t-test).
The striking defect in gluconeogenic gene expression in Vps15 mutants phenocopies the changes in the hepatic metabolism observed in FoxO1 LKO mice3334. FoxO1 is a master regulator of carbohydrate metabolism by positively controlling the expression of key gluconeogenesis enzymes G6PC and PEPCK3435. Consistently, transcriptional activity of FoxO1 is under negative control of insulin receptor signalling via Akt-mediated phosphorylation36. FoxO1 phosphorylation by Akt promotes its interaction with 14-3-3 proteins, nuclear exclusion and cytosolic degradation by the proteasome3738. In line with the increased stability of IR, Akt activation and increased FoxO1 phosphorylation observed in hepatic Vps15 mutants, FoxO1 levels were markedly decreased, while the interaction with 14-3-3 proteins was maintained in Vps15-depleted hepatocytes (Fig. 6a). Furthermore, FoxO1 protein levels in Vps15-depleted hepatocytes were partly rescued by treatment with the proteasome inhibitor MG132, suggesting an active proteasomal degradation of FoxO1 protein in mutant hepatocytes (Fig. 6b). Notably, a predominant cytoplasmic localization of FoxO1 was observed in Vps15 mutant hepatocytes by fractionation and immunofluorescence experiments (Fig. 6c,d). These results demonstrate that class III PI3K activity has a cell autonomous role in insulin signal transduction, FoxO1-dependent transcription and gluconeogenic programme.
Figure 6
FoxO1 expression and action is compromised in Vps15-depleted hepatocytes.
(a) Immunoblot analyses of GST-Sepharose eluates with anti-FoxO1 antibody (left panel). Recombinant 14-3-3-GST or GST proteins (2 μg) were coupled to Glutathione Sepharose 4B beads followed by incubation with 800 μg of total protein extracts of control or Vps15-depleted primary hepatocytes, which were collected 72 h post-transduction with Adeno-GFP or Adeno-CRE vectors. Decreased expression levels of FoxO1 protein was detected in total extracts of Adeno-CRE-infected hepatocytes used for the pull-down assay (right panel). (b) FoxO1 protein levels could be partially rescued by MG132 treatment of Vps15-depleted hepatocytes. After 72 h of transduction with Adeno-GFP or Adeno-CRE vectors hepatocytes were treated with 10 μM MG132 for 1 h before collected for further analysis. Immunoblot analysis of FoxO1 protein levels is presented. Immunoblot with anti-actin antibody serves as a loading control. Densitometric analyses of actin-normalized FoxO1 protein levels presented as folds over Adeno-GFP-transduced hepatocytes. Data are means±s.e.m. (n=3, *P<0.05 versus dimethylsulfoxide (DMSO), #P<0.05 versus GFP, two-tailed, unpaired Student's t-test). (c) Immunoblot analyses of nuclear and cytoplasmic fractions of control and Vps15-depleted primary hepatocytes 72 h post-transduction with Adeno-GFP or Adeno-CRE vectors with indicated antibodies. GAPDH and Lamin A/C are used as controls for cross-contamination of cytoplasmic and nuclear fractions, respectively. (d) Immunofluorescent analyses of FoxO1 subcellular localization in control and Vps15-depleted primary hepatocytes 72 h post-transduction with Adeno-GFP or Adeno-CRE vectors. Before fixation cells were either stimulated with1 μM insulin for 30 min or kept untreated in media without serum. Cells were PFA fixed and stained with anti-FoxO1 antibody, secondary anti-rabbit IgG Alexa Fluor 565 antibody was used for detection (images presented in green pseudocolour). Scale bar, 20 μm.
Improved Akt signalling on Vps15 depletion requires IR
The improved metabolic profile of Vps15 mutants prompted us to test the therapeutic benefits of Vps15 targeting in the models of metabolic challenge and insulin resistance. As a proof of concept, we first tested whether acute depletion of Vps15 ameliorated glucose metabolism of HFD-challenged mice. To this end, the Vps15f/f mice were subjected to short-term HFD feeding protocol and the glucose tolerance test (GTT) was performed 2 weeks later (Fig. 7a). Mice were then assigned to two experimental groups, which were injected either with CRE- or GFP-expressing adenoviral vectors. Five days postinjection mice were subjected to the GTT challenge. Unlike Adeno-GFP-treated mice, acute short-term depletion of hepatic Vps15 significantly ameliorated the glucose tolerance of HFD-fed Vps15f/f mice (Fig. 7a). Next, we asked whether the metabolic improvement on hepatic Vps15 inactivation was dependent on functional IR. To this end, we used a mouse model of inducible hepatocyte-specific depletion of IR, iLIRKO mutants. Two months after inducing the CRE-mediated recombination, iLIRKO mice developed significant glucose intolerance (Fig. 7b). Importantly, short-term Vps15 depletion using shRNA-expressing adenoviral vectors improved glucose tolerance in control, but not in hepatic IR mutants (Fig. 7b). Further molecular analysis in primary hepatocyte cultures of control and iLIRKO mice revealed that loss of IR expression precluded activation of Akt signalling by Vps15 downregulation (Fig. 7c). To rule out any chronic adaptation to hepatic IR loss, we also assayed the effect of Vps15 downregulation in the IR-depleted hepatocytes by transduction with Adeno-CRE vectors (Supplementary Fig. 12). Similarly to the cultures prepared from iLIRKO mice, the acute loss of IR impeded the Akt stimulation by Vps15 depletion (Supplementary Fig. 12).
Figure 7
Akt activation in cells depleted of Vps15 requires functional IR.
(a) Vps15f/f mice were submitted to HFD regime during 2 weeks followed by intraperitoneal GTT after overnight fast (pre-injection GTT or pre-injection CRE). Next, mice were divided into two groups and were transduced with either Adeno-GFP- or Adeno-CRE-expressing vectors. Five days post-transduction GTT was performed after overnight fast. Data are means±s.e.m. (n=5–6, *P<0.05 versus Adeno-GFP, two-tailed, unpaired Student's t-test). (b) Three-month-old iLIRKO and control mice were injected with tamoxifen to induce the IR deletion. Two-month postinjection iLIRKO and control mice were transduced with Adeno-GFP or Adeno-shRNA Vps15 vectors. Intraperitoneal GTT was performed in overnight-starved control and iLIRKO mice 5 days post-transduction. Mice were injected with 2 g kg−1 of glucose and glycaemia measured at indicated times. Data are means±s.e.m. (n=6–9, *P<0.05 versus Adeno-GFP, two-tailed, unpaired Student's t-test). (c) Primary hepatocytes prepared from control or iLIRKO mutant mice were transduced with Adeno-GFP or Adeno-shRNA Vps15 vectors. The 24-h post-transduction cells were starved and then stimulated with 1 μM insulin (Ins) for 1 h. Activation of IR-signalling pathway was revealed by immunoblot analysis. (d) Immortalized TSC2−/−;p53−/− and control TSC2+/+;p53−/− MEFs were transduced with Adeno-GFP or Adeno-shRNA Vps15 vectors. Cells were kept in the media in presence of 10% serum and were collected for analysis 24 h postinfection. Total protein extracts were analysed by immunoblotting. (e) Immortalized TSC2−/−;p53−/− and control TSC2+/+;p53−/− MEFs were transduced with Adeno-GFP or Adeno-shRNA Vps15 vectors. The 24-h postinfection cells were serum starved for 24 h followed by stimulation with 1 μM insulin for indicated times. Total protein extracts were analysed by immunoblotting with indicated antibodies. Immunoblot with anti-actin antibody served as a loading control.
To extend our observations on the effects of Vps15 inactivation on IR/Akt signalling, we used an additional model of insulin resistance. Previous works demonstrated that loss of tumour suppressor tuberous sclerosis complex 2 (TSC2) gene leads to insulin resistance due to reduction in Akt phosphorylation39. The latter is ascribed to mTORC1-dependent negative feedback mechanisms and the defects in mTORC2 activation3940. The expression of IRβ was strikingly downregulated in TSC2-null cells, suggesting additional mechanism of regulation (Fig. 7d). Importantly, unlike IGF1R, IRβ levels could be rescued by depletion of Vps15 in TSC2-deficient mouse embryonic fibroblasts (MEFs) (Fig. 7d). Normalization of IRβ levels was paralleled by increase in Akt phosphorylation (Fig. 7d). Significantly, the depletion of Vps15 in TSC2-null MEFs improved insulin-stimulated Akt activation and phosphorylation of its downstream target—Pras40 (Fig. 7e). In sum, the increase of Akt signalling on Vps15 depletion is IR dependent and may rescue the defect in the model of IR resistance due to TSC2 inactivation.
Metabolic amelioration on acute Vps15 inactivation in vivo
To further test whether the Vps15 depletion could have therapeutic benefits in vivo in animal models of diabetes and insulin resistance, the ob/ob mice were injected with adenoviral vectors expressing shRNA against Vps15. One week after injection, the body weight, liver and peripheral organ weight were not modified by the treatment (Supplementary Fig. 13a). Importantly, this treatment led to a 70% and a 50% decrease in hepatic Vps15 transcript and protein levels, respectively (Supplementary Fig. 13b,c). At the same time, the expression of Vps15 in WAT and muscle tissues was unmodified (Supplementary Fig. 13d). Downregulation of hepatic Vps15 was accompanied by impaired autophagic processing of LC3 and accumulation of p62 in the livers of shRNA Vps15-treated mice (Supplementary Fig. 13c,e). Remarkably, hepatic downregulation of Vps15 significantly improved glucose tolerance of ob/ob mice (Fig. 8a,b). This was accompanied by a decrease in liver steatosis on Vps15 depletion (Fig. 8c). The plasma metabolite levels were not modified by the treatment (Supplementary Fig. 14a). The decrease in hepatic triglyceride levels was accompanied by reduction of lipogenic transcription activators and lipogenic enzyme expression (Supplementary Fig. 14b,c). The expression of the lipases was induced in the livers of ob/ob mice on Vps15 depletion suggesting the induction of lipolysis (Supplementary Fig. 14b). Expression of PGC1α transcriptional coactivator was significantly decreased (Supplementary Fig. 14b). The expression of glycolytic enzymes HK2 and PKM2 was markedly induced (Supplementary Fig. 14c). Similarly, hepatic Vps15 downregulation reverted glucose intolerance in wild-type mice fed for short term with HFD (Supplementary Fig. 14d). Altogether, the acute depletion of Vps15 in livers improves the metabolic parameters in genetic and diet-induced animal models.
Figure 8
Depletion of hepatic Vps15 improves metabolic phenotype of ob/ob mice.
(a) Intraperitoneal GTT in overnight-starved ob/ob mice 7 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. Mice were injected with 1 g kg−1 of glucose and glycaemia measured at indicated times. Data are means±s.e.m. (n=4–6, *P<0.05 versus Adeno-shRNA SCR, two-tailed, unpaired Student's t-test). (b) The histogram of an average value of the area under the respective curve presented in a was calculated with GraphPadPrizm5 software. Data are means±s.e.m. (n=4–6, *P<0.05 versus Adeno-shRNA SCR, two-tailed, unpaired Student's t-test). (c) Oil red staining of frozen liver sections of random-fed ob/ob mice killed 8 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors (left panel), scale bar, 50 μm. Triglyceride (TG) content measured enzymatically in livers of random-fed ob/ob mice 8 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors (right panel). Data are means±s.e.m. (n=4–6, *P<0.05 versus Adeno-shRNA SCR, two-tailed, unpaired Student's t-test). (d) Immunoblot analyses of liver extracts from random-fed ob/ob mice 8 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. Densitometric analyses of phosphoprotein levels normalized to total protein levels presented as folds over shRNA SCR. Data are means±s.e.m. (n=4–5, *P<0.05 versus Adeno-shRNA, two-tailed, unpaired Student's t-test). (e) Immunoblot analyses of p85αPI3K immunoprecipitated in complex with IRβ. IRβ was immunoprecipitated with anti-IRβ antibody from liver total protein extracts of random-fed ob/ob mice sacrificed 8 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. Densitometric analysis of p85αPI3K normalized to immunoprecipitated IRβ protein levels is presented. Data are means±s.e.m. (n=3–6, *P<0.05 versus Adeno-shRNA SCR). (f) Immunofluorescence analyses of formalin-fixed paraffin-embedded liver sections from random-fed ob/ob mice 8 days post-transduction with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors with anti-IRβ antibody. Secondary anti-rabbit IgG Alexa Fluor 565 antibody was used for detection (images presented in green pseudocolour). Scale bar, 10 μm.
Vps15 depletion improves hepatic IR signalling in ob/ob mice
In line with our earlier observations, shRNA silencing of hepatic Vps15 in obese mice resulted in a sharp activation of Akt as evidenced by Ser473 and Thr308 phosphorylation (Fig. 8d). The activation of the pathway was further corroborated by a significant increase in the phosphorylation of Akt substrates—Pras40 and FoxO1 (Fig. 8d). The phosphorylation of Akt substrates was not modified in muscles and fat tissue of treated mice (Supplementary Fig. 13d). In addition, immunoprecipitation analyses with anti-IRβ antibody revealed that p85αPI3K was more abundant in the complexes precipitated from the extracts of livers of shRNA Vps15-treated mice as compared with controls (Fig. 8e). Finally, we asked whether IR localization is affected in shRNA Vps15-transduced mice. Microscopic examination of liver sections of shVps15-treated mice revealed marked increase in IRβ-positive endosomes (Fig. 8f). Taken together, our data suggest that selective inhibition of hepatic class III PI3K may have beneficial consequences in conditions of T2D and metabolic syndrome, by ameliorating glucose metabolism through improved IR signalling.
Discussion
In this study we provide experimental evidence that class III PI3K is regulated by insulin in hepatocytes and in turn modulates IR signalling to insure whole-body metabolic responses. We show that UVRAG-associated class III PI3K interacts with IR and is activated by insulin, with kinetics that are consistent with a role in IR endocytosis and trafficking. Interference with the expression of the regulatory subunit in the class III PI3K complex, Vps15, results in three novel and yet unreported outcomes: (i) defects of IR degradation and increased Akt signalling accompanied by profound perturbations in endocytic trafficking; (ii) blunted gluconeogenesis concomitant with nuclear exclusion of FoxO1 transcription factor and defects in FoxO1-dependent gene expression; and (iii) amelioration of metabolic syndromes in genetic and diet-induced animal models. These data reveal a previously unappreciated role of class III PI3K in the control of insulin sensitivity and metabolic adaptations.How class III PI3K activity is regulated by extracellular signals has been a long-standing question in the field. Insulin, glucose and amino-acid levels that effectively modulate endocytosis and autophagy, have deceivingly modest effects on total Vps34 lipid kinase activity222441. An explanation has recently came from the demonstration that glucose and amino-acid starvation stimulate specific Vps34-containing complexes without having a significant effect on the total Vps34 activity in some cells2223. However, the effect of insulin on specific complexes has never been tested. In the present study we show that, while amino-acid starvation potently induces ATG14-containing class III PI3K activity, insulin stimulation selectively promotes the activity of UVRAG-containing class III PI3K (Fig. 3). Importantly, this evidence provides a regulatory mechanism for the reported functions of these distinct complexes, that is, the induction of autophagy during nutrient starvation by the ATG14-containing complex and the promotion of endocytic trafficking during growth factor stimulation by the UVRAG-containing complex. How insulin specifically stimulates UVRAG-containing complexes will require further investigation. Interestingly, we show that IR is found in complex with class III PI3K (Fig. 3c,d and Supplementary Fig. 3c). Bioinformatic analysis by online resource ScanSite3 (ref. 42) suggests the presence in UVRAG and Vps15 of putative SH2-binding domains that recognize phospho-tyrosine. In addition, both UVRAG and Vps15 are identified as tyrosine phosphorylated proteins in independent phosphoproteome studies including those accessible in Phosphosite database43. It is therefore possible a direct action of IR/IRS on UVRAG-containing class III PI3K complexes, similar to the known effect on class I PI3K. Consistently, another component of class III PI3K complex, Beclin-1, has been recently reported to be tyrosine phosphorylated by epidermal growth factor receptor, resulting in inhibition of Vps34 activity44. However, we cannot exclude intermediate steps, possibly involving the Rab family of small GTPases, which are also actively involved in endosomal trafficking and found in complex with class III PI3K454647. Of note, Rab5 has been shown to co-localize with IR in endosomes and its GTP loading is potently stimulated by insulin48. In addition, Rab7 can interact with class III PI3K complexes and stimulate its activity4549. Therefore, the crosstalk between IR-Rab5/Rab7-Vps34/Vps15/UVRAG is likely to exist at distinct levels in insulin-stimulated cells.We demonstrate that depletion of Vps15 increases insulin sensitivity in different models both in vitro and in vivo (Figs 1, 4, 7 and 8). This suggests that Vps34/Vps15 complex is involved in a feedback regulatory loop that, on insulin stimulation, contributes to the modulation of IR function. The effects of class III PI3K inactivation are complex. At current stage, it is difficult to separate the general trafficking defect due to PI3P depletion from potential novel direct mechanisms of class III PI3K on IR function. However, it is likely that the IR-signalling perturbations we observed on Vps15 depletion are due to compromised endocytic trafficking of the receptor. The reduced velocity of IR-positive endosomes (Fig. 2b,c and Supplementary Movie) together with the striking reorganization of the endosomal compartment (Figs 1d and 2a and Supplementary Figs 1d, 2d and 6g) suggest that trafficking defects might largely contribute to the delayed receptor degradation. In these conditions, prolonged residence of IR in endosomes would contribute to the amplified insulin signalling that we measured. Indeed, key insulin signal transduction elements are found at endosomal membranes including IRS, class I PI3K and Akt7. Accordingly, preventing IR degradation by blocking its intracellular transport resulted in similar increase in insulin-dependent signalling (Fig. 2d). Of note, an endosomal protein, APPL1, has been reported to favour downstream insulin signalling through the Akt pathway5051. APPL1 was identified in protein interaction screens as a binding partner of Akt and an adaptor protein positively regulating Akt activity525354. It has been shown to favour the recruitment of IRS proteins to the IR and to release Akt from the binding to TRB3, its endogenous inhibitor5051. Consistently, in vivo studies using gain- or loss-of-function approaches have confirmed the positive role of APPL1 on insulin sensitivity5051. Interestingly, PI3P is required for the maturation of APPL1-positive endosomes to sorting endosomes54. It would be interesting to test whether loss of functional class III PI3K affects APPL1+ endosomes contributing to the observed metabolic responses.In addition, it is plausible that the endosomal sorting and lysosomal degrading activities are lower in Vps15-depleted livers, partly accounting for the slower kinetics of IR downregulation after insulin stimulation. In a previous study on skeletal muscles, we have shown that the lysosomal function is affected by the Vps15 depletion due to sorting defects of proteolytic enzymes26. Of note, chloroquine, a drug that interferes with the acidification of the endosomes, prevents dissociation of insulin from its receptor and subsequent receptor degradation, also potentiates insulin action and has beneficial effects on glucose homeostasis6555657.Massive vacuolation is a characteristic morphological change in the cells depleted of Vps15 apparent both in vitro and in vivo. Despite highly resembling the steatosis, the histological analyses by Oil Red and Bodipy staining did not reveal apparent accumulation of neutral lipids in hepatic tissue neither on acute or chronic Vps15 depletion. Furthermore, the acute Vps15 downregulation in the livers of obese mice decreased triglyceride levels. At first sight, those are unexpected observations as hepatic inactivation of essential autophagic genes, Atg5 and Atg7, was reported to induce steatosis due to defective lipophagy143132. However, we cannot exclude that other types of lipids that could not be revealed by the analyses performed (for example, polar lipids, including sphingolipids, phospholipids and ceramides) accumulate on Vps15 depletion. This is in line with the observations of increased phospholipid content on chronic chloroquine treatment, which provoke cytoplasmic vacuolation in different cell types including hepatocytes58. In addition, the vacuolation of hepatocytes could be a morphological manifestation of cytoplasmic accumulations of various substances, including water and glycogen, all having similar morphology. Those structures could originate from different membranes including plasma membrane, endosomal compartment, Golgi apparatus, lysosomes or autophagolysosomes at the different stages of the maturation. The subcellular origin and the content of abundant vacuolar structures in Vps15-depleted cells require further studies. From the other hand, the relationship between defective autophagy and the steatosis as well as steatosis and insulin resistance are not completely understood. Of note, increased insulin sensitivity of hepatocyte-specific PTEN mouse mutants is accompanied by severe steatosis and defective autophagy5960. In contrast, hepatic mutants of TSC1, which are characterized by severe autophagy block and insulin resistance, are protected from diet-induced steatosis6162. Considering that class III PI3K controls both autophagy and endocytic trafficking, the effects of its inactivation will be manifested on multiple levels.The role of FoxO1 transcription factor as a chief regulator of gluconeogenic responses in the liver is firmly established3334356364. In addition, interference with FoxO1 activity or expression in mouse models of obesity or insulin resistance significantly improves glucose tolerance356364. These observations are highly reminiscent of the Vps15 LKO mouse phenotype (Figs 4, 5, 7 and 8 and Supplementary Figs 7 and 14). Similarly to therapy with Foxo1 antisense oligonucleotides in DIO mice35, depletion of Vps15 in ob/ob mice improves steatosis and glucose metabolism (Fig. 8a–c). The best documented point of control of FoxO1 is Akt-dependent phosphorylation and inactivation in response to insulin36. In line with blunted gluconeogenesis observed in Vps15-depleted hepatocytes and in vivo, we detect increased phosphorylation of FoxO1 on Vps15 inactivation. Our observations in Vps15 LKO mice (Figs 4, 5, 6) are in agreement with the established mechanism of IR/Akt-dependent FoxO1 phosphorylation, leading to nuclear exclusion and proteasomal degradation3738. However, we cannot rule out the possibility that the striking suppression of FoxO1 function in Vps15-depleted hepatocytes is also the consequence of a direct action of class III PI3K on FoxO1.The central role of endocytic and autophagic trafficking in nutrient/growth factor sensing and homeostasis has prompted numerous studies on the metabolic consequences of their functional alterations. The physiological importance of autophagy for the maintenance of glycaemia during the perinatal period before lactation is illustrated by the perinatal lethality of the mouse autophagy mutants3165. Defective autophagy is discussed both as a causative factor as well as accompanying state in many pathological conditions10. Mouse models of obesity display autophagy defects and the metabolic syndrome could be improved by increasing autophagic flux through Atg7 overexpression or by autophagy enhancers1415. However, a defect in autophagic flux in skeletal muscles or liver by Atg7 deletion may also lead to increased circulating levels of Fgf21 and protect from the detrimental effects of HFD feeding13.Here we show that in vivo hepatic depletion of Vps15 has strikingly different outcomes on whole-body nutrient homeostasis as compared with autophagy mutants. Despite the involvement of class III PI3K in autophagy, the metabolic effects of hepatic Vps15 depletion can be ascribed to a prominent role on IR endocytic trafficking and signal transduction through the alteration of a retrograde signalling mechanism. Defects of IR endocytosis trafficking and degradation are reported in metabolic conditions accompanied by hyperinsulinemia, such as genetic forms of obesity and T2D111266. Our data reveal the impact of altering Vps34/Vps15 function in metabolic syndromes and suggest a novel therapeutic target in these diseases.
Methods
Reagents
The following primary antibodies were used: Vps15 (1:1,000, Abnova, H00030849-M03; or 1:1,000, Genetex, GTX108953); p62 (SQSTM) (1:3,000, Abnova, H00008878-M01); Tubulin (1:5,000, Sigma, T9026); β-actin (1:50,000, Sigma, A5316); Beclin-1 (1:1,000, Cell Signaling, 3495); pSer473 Akt (1:1,000, Cell Signaling, 9275); pThr308 Akt (1:1,000, Cell Signaling, 9275); Akt (1:1,000, Cell Signaling, 9272); pThr246 Pras40 (1:1,000, Cell Signaling, 2997); Pras40 (1:1,000, Cell Signaling, 2691); GAPDH (1:1,000, Santa Cruz, SC-25778); pY IRβ (1:1,000, Cell Signaling, 3024 and 3021); Rab5 (1:1,000, Cell Signaling, 3547); Rubicon (1:1,000, Cell Signaling, 8465); pThr24/32 FoxO1/3a (1:1,000, Cell Signaling, 9464); pSer256 FoxO1 (1:1,000, Cell Signaling, 9461); FoxO1 (1:1,000, Cell Signaling, 2880); Lamin A/C (1:1,000, Cell Signaling, 2032); GST (1:5,000, Santa Cruz, SC-459); IGF1R (1:1,000, Cell Signaling, 9750); p85α PI3K (1:1,000, Santa Cruz, SC-423); IRS1 (1:500, Millipore, 06-248); UVRAG (1:1,000, Cell Signaling, 13115); Atg14 (1:1,000, Cell Signaling, 5504); Vps34 (1:1,000, Cell Signaling, 4263); LC3 (1:1,000, NanoTools, 0231-100/LC3-3-5-5F10); Ub (1:1,000, Cell Signaling, 3963); FAS (1:1,000, Cell Signaling, 3180); ATPCL (1:1,000, Cell Signaling, 4332); HK2 (1:1,000, Cell Signaling, 2867); PKM2 (1:1,000, Cell Signaling, 4053); Enolase (1:1,000, Santa Cruz, SC-7455); PPARγ (1:1,000, Cell Signaling, 2435); ACC (1:1,000, Cell Signaling, 3662); Flag-tag (1:1,000, Sigma, F3162); LAMP1 (1:1,000, Abcam, ab24170); LAMP2 (1:1,000, Abcam, ab13524); BrdU (1:500, Roche, 11170376001); β-catenin (1:500, BD Biosciences, 610153); VDAC (1:1,000, Calbiochem, AB10527); G6PC (1:1,000, Santa Cruz, SC-33839 and a kind gift of Gilles Mithieux (INSERM U855, France)); PEPCK (1:1,000, Santa Cruz, SC-32879); and IRβ (1:1,000, Santa Cruz, SC-711). For class III PI3K in vitro activity antibodies were from MBL International ATG14 (PD026) and UVRAG (M160-3). Vps34 antibody used for class III PI3K in vitro activity was from Echelon Biosciences (Z-R015). GFP and GFP-CRE adenoviral vectors were described previously26. Adenoviral vector expressing shRNA Vps15 was generated and amplified by VectorBiolabs (USA). Adenovirus expressing shRNA Scrambled was kindly provided by Stephan Herzig (Institute for Diabetes and Cancer, Germany). 2xFYVE-GFP-expressing vector was kindly provided by Sharon Tooze (CRUK, UK). hIRβ-RFP-overexpressing vector was kindly provided by Ingo B. Leibiger (Karolinska Institutet, Sweden).
Animals
The Vsp15 conditional mutant mouse line was established at the MCI/ICS (Mouse Clinical Institute—Institute Clinique de la Souris, Illkirch, France) as described in ref. 26. For generation of liver-specific Vps15 knockout mouse line, Vps15 floxed mice were crossed with transgenic mice expressing Cre recombinase under the control of a Rat albumin promoter30. For the genotyping genomic DNA isolated from mouse tail snip or tissues was analysed by PCR. The primer sequences are listed in Supplementary Table S1. The following combinations of the primers were used: to check presence of distal loxP sites—LF/LR; to check Cre-mediated excision of the locus—LF/ER. For generation of liver-specific IR knockout mouse line, mice carrying the LoxP sites flanking the fourth exon of the IR gene (IRlox/lox stock number: 006955; Jackson laboratory, USA) were intercrossed with C57BL/6J, which specifically express the Cre recombinase in the liver under the transthyretin promoter (TTR-CreTam mice; kind gift of Mireille Vasseur, Institut Cochin, France)67. The resulting IRlox/+;TTR-CreTam mice were interbred with IRlox/lox mice to generate IRlox/lox;TTR-CreTam mice, named iLIRKO (for inducible liver insulin receptor knockout). To knockout the IR gene, 12-week-old male mice were submitted to an intraperitoneal tamoxifen injection (1.5 mg per mouse) during three consecutive days. The efficient deletion of IR specifically in hepatocytes was observed 2 weeks postinjection. iLIRKO mice 8 weeks postinjection with the tamoxifen were used for the in vivo experiments. Five-week-old male ob/ob and C57Black/6 mice were purchased from Janvier (France). Mice were acclimatized for 2 weeks in the animal facility before the initiation of the treatments. Male mice were used for the experimentation. All animal studies were approved by the Direction Départementale des Services Vétérinaires, Préfecture de Police, Paris, France (authorization number 75-1313).
Treatments and metabolic studies in vivo
All animals used in the study were fed ad libitum standard chow diet (Teklad global protein diet; 20% protein, 75% carbohydrate and 5% fat). Where indicated, mice were fed with HFD (Diet D12492(I) SNIFF Diet; 20% protein, 20% carbohydrate and 60% fat) for 2 weeks before manipulations. For 5-bromo-2′deoxyuridine (BrdU) incorporation, mice were treated with BrdU (3 mg ml−1, Sigma-Aldrich) dissolved in drinking water for 3 days before killing. Animals were killed between 14:00 and 16:00 unless indicated. For immunohistochemical analysis liver tissue was fixed overnight in phosphate-buffered 10% formalin and embedded in paraffin. In all, 6-μm sections were cut and processed either for staining with eosin/hematoxylin or for immunohistochemical analyses. Glucose and pyruvate tolerance test were performed in 6-week-old Vps15 LKO mice after an overnight fasting (14 h). Insulin tolerance test was performed on 6-h starved 6-week-old control and Vps15 LKO mice. Mice were injected intraperitoneally with glucose (Vps15f/f, Vps15 LKO, iLIRKO, chow-fed wild-type and HFD-fed wild-type mice—2 g kg−1, ob/ob—1 g kg−1), Humalog insulin (1 μ kg−1) or pyruvate (2 g kg−1), and blood was collected from the tail vein for determination of glucose levels at different time points using Glucotrend glucometer (Roche Diagnostics). Triglyceride levels in the acetone extracts of liver tissue were determined using Triglycerides FS Kit (Diasys) according to the manufacturer's instructions and as described68.
Cell culture
Mouse hepatoma cell line Hepa1.6 was obtained from American Type Culture Collection. Immmortalized TSC2−/−;p53−/− MEFs and the littermate-derived pair wild-type control cells were provided by D. J. Kwiatkowski (Brigham and Women's Hospital, Boston, MA) and were described previously69. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 50 U ml−1 penicillin and 50 μg ml−1 streptomycin. To achieve Vps15 depletion, Hepa1.6 cells and MEFs were infected with 50 m.o.i. (multiplicity of infection) of Adeno-shRNA Vps15 or as a control with Adeno shRNA SCR or GFP-expressing vectors. Cells were collected 48 h later for the analyses. For insulin treatment, 24 h postinfection cells were starved in Dulbecco's modified Eagle's medium without FBS for 24 h and then were stimulated with insulin (final concentration 1 μM) for indicated times.Primary hepatocytes from 4–6-week-old mice were isolated by liver perfusion as described previously68. Hepatocytes were plated at 12 × 104 cells per cm2 in Williams medium (Life Technologies) supplemented with 20% FBS, 100 nM Insulin, 25 nM dexamethasone, penicillin (100 U ml−1), streptomycin (100 μg ml−1) and amphotericin B (Fungizone; 250 ng ml−1). To achieve Vps15 deletion Vps15f/f hepatocytes 12 h after plating were infected with 10 m.o.i. of Adeno-CRE or as a control with Adeno-GFP vectors, 2 h after addition of viral particles the media was changed to Williams medium supplemented with mix of antibiotics and 25 nM dexamethasone, and when indicated 10% FBS and 100 nM insulin were added. Cells were collected 72 h later for the analyses. For insulin treatment, hepatocytes 72 h postinfection were stimulated with 1 μM insulin for different times.
Glucose production in primary hepatocytes
Primary hepatocytes were plated in 12-well plates. The 12-h post-platting cells were infected with Adeno-shRNA SCR or Adeno-shRNA Vps15 vectors. The 48-h postinfection cells were washed once with PBS, and glucose production was determined after 12 h of incubation in Krebs salts solution supplemented with lactate/pyruvate mix (10:1 mM). The amount of glucose released into the medium was determined by evaluating the production of NADPH from NADP in the presence of hexokinase and glucose-6-phosphate dehydrogenase using commercially available kit (Sigma) and normalized to the total protein content in each well determined by Bradford assay (BioRad).
Subcellular fractionation and endosome preparation
Nuclear extracts were prepared using NE-PER Kit (Pierce) according to the manufacturer's recommendations, from 1 × 106 cells. Endosomal fraction was purified using sucrose step gradient as described70. Briefly, cells were washed with PBS and were pelleted by centrifugation at 200g for 5 min. The equal mass of cells was used for each condition. The pellet was resuspended in homogenization buffer (HB: 250 mM sucrose (8.6%), 3 mM imidazole (pH 7.4), supplemented with protease inhibitors (Roche)) and was homogenized by seven passes through a G25 needle. Post-nuclear supernatant (PNS) was obtained by centrifugation at 2,000g for 10 min. Then, sucrose concentration of the PNS was adjusted to 40.6% and PNS was transferred to SW41 ultracentrifuge tube (Beckman-Coulter). Next, 35% sucrose in 3 mM imidazole buffer (pH 7.4) was layered on PNS up to the top of the tube. The sample was centrifuged at 210,000g for 3 h at 4 °C. Crude endosomes were collected from the interphase between 35% sucrose and HB buffer.
Microscopy
For fluorescent microscopy analyses, hepatocytes were grown on collagen-treated coverslips (Millipore). The 12-h post-plating primary hepatocytes were transfected with corresponding plasmids using Lipofectamine 2000 reagent as recommended by the manufacturer (Life Technologies). For the microscopy analyses 24 h post-transfection cells were fixed with 4% paraformaldehyde in PBS for 20 min and permeabilized with 0.1% saponin in PBS for 10 min, followed by blocking in 3% BSA in PBS. Slides were then treated with primary antibodies for 1 h or directly analysed by fluorescent microscopy. Secondary antibodies used for these assays were anti-rat IgG Alexa Fluor 635 (Life Technologies) or anti-rabbit IgG Alexa Fluor 488 or 565 (Life Technologies). Confocal images were acquired with an optical slice of 0.8 μm using a × 40/0.75 oil immersion objective using LSM 700 confocal microscope (Zeiss) and analysed using ZEN software (Zeiss). Fluorescence and light microscopy were performed using an inverted microscope (Eclipse Ti-S; Nikon) and × 10/0.30, × 20/0.50 or × 40/0.785 Plan Fluor objectives (Nikon). Images were captured using a Super high-definition cooled colour camera head DS-Ri1 (Nikon) and NIS Elements software (Nikon). All samples for microscopy were viewed at room temperature.For spinning disk microscopy, cells plated onto glass-bottom dishes and transfected with the indicated constructs were imaged for exposure times of 200 ms at 5-s intervals for 240 s using a spinning disk microscope (Andor) based on a CSU-W1 Yokogawa head mounted on the lateral port of an inverted IX-83 Olympus microscope equipped with a × 60 objective lens and a 491 nm 100 mW laser (Andor) used at 40% of maximum power. Images were acquired with a sCMOS camera (Andor). The system was steered by Metamorph 7 software.
Protein extraction, immunoblotting and immunoprecipitation
To prepare protein extract for immunoblot analysis, cells were washed twice with cold PBS, scraped from the dishes in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 5% glycerol, 138 mM NaCl, 2.7 mM KCl, 1% NP-40, 20 mM NaF, 5 mM EDTA, 1 × protease inhibitors (Roche) and 1 × PhosphoStop Inhibitors (Roche). The same buffer was used to prepare protein extracts from liver tissue. Homogenates were spun at 12,000g for 10 min at 4 °C. For immunoprecipitation 1 mg of cleared protein extract was incubated with 1 μg of anti-Flag M2 (Sigma), anti-IRβ antibody (Santa Cruz), anti-UVRAG (MBL) or anti-p85αPI3K antibody (Santa Cruz) for 2 h at 4 °C. Then, immune complexes were pulled down using Protein G Sepharose beads (GE) during 1 h followed by four washes with extraction buffer. Protein extracts or immunoprecipitates were resolved by SDS–polyacrylamide gel electrophoresis before transfer onto PVDF membrane followed by incubation with the primary antibodies and horseradish peroxidase-linked secondary antibodies. Immobilon Western Chemiluminescent HRP Substrate (Millipore) was used for the detection.
In vitro Vps34 lipid kinase assay
Cells were lysed in Mild Lysis Buffer (MLB: 10 mM Tris, pH7.5, 2 mM EDTA, 100 mM NaCl, 1% NP-40, 50 mM NaF, 1 mM Na3VO4 and protease inhibitor cocktail (Roche)). Total protein extracts were cleared by 10-min centrifugation at 11,000g. For immunoprecipitation, the indicated antibody was coupled with protein G Sepharose (GE). The antibody-conjugated beads were added to the cell lysates and incubated at 4 °C for 2 h. Beads were washed with MLB four times and one time with kinase buffer (KB: 20 mM HEPES (pH 7.4), 1 mM EGTA, 0.4 mM EDTA and 5 mM MgCl2). One-half volume was then taken for input, the remainder was centrifuged and excess 1 × KB was removed. A volume of 40 μl of 1 × kinase assay buffer was added to the beads supplemented with 0.1 mg ml−1 phosphatidylinositol, 50 μM cold ATP, 5 μCi 32 P-ATP, 5 mM MnCl2 and 50 μM dithiothreitol followed by incubation at 37 °C for 30 min with vigorous shaking. Reaction was quenched by addition of 10 μl 1 M HCl, followed by lipid extraction with 2 volumes of MeOH:CHCl3 (1:1). Aqueous phase was discarded and organic phase loaded on a thin layer chromatography plate (Whatman). Resolution of phospholipid was achieved using a buffer composition of CHCl:MeOH (99%):NH4OH (30%):Water (129:100:4.29:24). Resolved plates were analysed by autoradiography.
Real-time quantitative PCR
Total RNA was isolated from tissue by RNAeasy Lipid Tissue Mini Kit (Qiagen) and RNeasy Mini Kit (Qiagen) from primary hepatocytes. Single-strand complementary DNA was synthesized from 1 μg of total RNA using 125 ng of random hexamer primers and SuperScript II (Life Technologies). Real-time quantitative PCR was performed on MX3005P instrument (Agilent) using a Brilliant III Ultra-Fast QPCR Master Mix (Agilent). The relative amounts of the mRNAs studied were determined by means of the 2−ΔΔCT method, with pinin or cyclophilin as reference genes and control treatment or control genotype as the invariant control. The primer sequences are listed in Supplementary Table S1.
Statistical analysis
A two-tailed Student's t-test was used for statistical analysis unless indicated. All data are expressed as means±s.e.m., and significance was established at the P≤0.05 level.
Additional information
How to cite this article: Nemazanyy, I. et al. Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling. Nat. Commun. 6:8283 doi: 10.1038/ncomms9283 (2015).
Authors: S Christoforidis; M Miaczynska; K Ashman; M Wilm; L Zhao; S C Yip; M D Waterfield; J M Backer; M Zerial Journal: Nat Cell Biol Date: 1999-08 Impact factor: 28.824
Authors: Varman T Samuel; Cheol Soo Choi; Trevor G Phillips; Anthony J Romanelli; John G Geisler; Sanjay Bhanot; Robert McKay; Brett Monia; John R Shutter; Richard A Lindberg; Gerald I Shulman; Murielle M Veniant Journal: Diabetes Date: 2006-07 Impact factor: 9.461
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391